{"id":"NCT01888484","sponsor":"Octapharma","briefTitle":"Study of Octanorm Subcutaneous IG in Patients With PID","officialTitle":"Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2020-06-09","completion":"2020-06-09","firstPosted":"2013-06-27","resultsPosted":"2021-08-17","lastUpdate":"2021-08-17"},"enrollment":75,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency Disorder"],"interventions":[{"type":"BIOLOGICAL","name":"octanorm 16.5%","otherNames":[]}],"arms":[{"label":"Octanorm 16.5%","type":"EXPERIMENTAL"}],"summary":"This is an open-label phase III study with a 12-week wash-in/wash-out period followed by a 12-month efficacy period. The main goals of the study are to assess the efficacy of octanorm in preventing serious bacterial infections (SBI) compared with historical control data and to evaluate the pharmacokinetic (PK) characteristics of octanorm.","primaryOutcome":{"measure":"Rate of SBI Per Person-year","timeFrame":"Every 4 weeks until the final evaluation at week 65.","effectByArm":[{"arm":"All Patients","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["United States","Canada","Czechia","Hungary","Poland","Russia","Slovakia"]},"refs":{"pmids":["30778345"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":75},"commonTop":["Any infusion site reaction","Upper respiratory tract infection","Nasopharyngitis","Sinusitis","Cough"]}}